New eye test could spot retinal disease faster
NCT ID NCT03065881
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a device called RETeval that measures how the retina responds to light. Researchers collected data from 664 people, both with and without retinal disease, to create a reference for normal eye function. The goal is to improve diagnosis of retinal conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
664 people
The number who actually took part.
- Started
-
Feb 2017
- Finished
-
Dec 2021
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 months to 95 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All volunteers (age 0.5 to 95) willing to participate in the study as a part of their routine eye exam. * While not specifically targeting vulnerable groups such as for example children and pregnant women, we invite them to participate in the study. Collecting normative data from these less represented populations is particularly difficult and we welcome the opportunity to gather these rare data. * Subjects under the age of 18 will be included with the assent of the subject (for those at least 10 years of age) and consent from one parent/guardian (for those under age of 10). * In any case patient is not able to provide the consent by him/her self and is willing to participate in the study the same person that is consenting for the routine eye exam can consent for the REACT study. Exclusion Criteria: * Subjects with photosensitive epilepsy , allergies to pupil dilating agents, or history of cardiac dysrhythmia will not be invited to participate in this study. - Subjects with history of glaucoma can either be included in the group of non dilated subjects or can have dilated ERGs if the dilation was recommended by the health professional as the part of the routine eye exam. * Exclusion criteria will be based on volunteer's providing this information at the time of signing the consent form. * If patient is not aware of his photosensitive epilepsy and it occurs during the recording, the test will be interrupted immediately. * Statistically, 1 person out of 3600 people can suffer from photosensitive epilepsy in US. * There is a rather small possibility we will encounter such a person during the collection of ERGs from the group of 1000 volunteers
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Retinal disease, electroretinogram are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Little Rock Eye Clinic
Little Rock, Arkansas, 72205, United States